Health in Old Age

Abstract

Get full access to this article

View all access options for this article.

References

Bryant

J. M.

Schvartz

Torosdag

Fertig

Fletcher

L. J. R.

Schwartz

M. S.

Quan

R. B. F.

(1963). Long-term antihypertensive effect of pargyline HCl with and without diuretic sulphonamides. Ann. N.Y. Acad. Set., 107, 1023

Corcoran

A. C.

Loyke

H. F.

(1962). Mebutamate as antihypertensive agent in outpatients. J. Amer. med. Ass., 181, 1043

Drug and Therapeutics Bulletin (1964). 2, 15

Janney

J. G.

Pierre

G. D.

Thurmann

Atley

J. H.

Aykent

Castro

(1963). Clinical evaluation of Mebutamide: A new antihypertensive agent. Clin. Pharmacol. Ther., 4, 720

Johnston

A. W.

Prichard

B. N. C.

Rosenheim

M. L.

(1962). Adrenergic neurone-blocking agents. Lancet, 2, 996

Lawrie

T. D. V.

Lorimer

A. R.

McAlpine

S. G.

Reinert

(1964). Clinical trial and pharmacological study of Compound 1029 (‘Vatensol’). Brit. med. J., 1, 402

Maronde

R. F.

Haywood

L. J.

(1963). Evaluation of the monoamine oxidase inhibitor, Pargyline, as an antihypertensive agent: A. Clinical results. Ann. N.Y. Acad. Sci., 107, art. 3, 975

Montuschi

Pickens

P. T.

(1962). A clinical trial of two related adrenergic-neurone-blocking agents, B.W. 392C60 and B. W. 467C60. Lancet, 2, 897

Peart

W. S.

Macmahon

M. T.

(1964). Clinical trial of 2-Guanidino-methyl (1, 4) Benzodioxan (Compound 1003). Brit. med. J., 1, 398

10.

Smirk

(1963). The hypotensive action of B.W. 467C60. Lancet, 1, 743